Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 1,200 Shares

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,200 shares of Pro-Dex stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $47.76, for a total value of $57,312.00. Following the transaction, the director now directly owns 359,646 shares in the company, valued at $17,176,692.96. The trade was a 0.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Pro-Dex Stock Performance

Shares of PDEX opened at $45.00 on Wednesday. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The firm’s fifty day simple moving average is $48.12 and its two-hundred day simple moving average is $32.49. Pro-Dex, Inc. has a 12 month low of $16.18 and a 12 month high of $59.60. The stock has a market capitalization of $146.66 million, a P/E ratio of 29.22 and a beta of 0.56.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in PDEX. FMR LLC increased its holdings in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after purchasing an additional 1,028 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after buying an additional 900 shares during the period. Bard Associates Inc. lifted its position in shares of Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after acquiring an additional 2,031 shares during the period. JPMorgan Chase & Co. boosted its stake in Pro-Dex by 2.2% during the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after acquiring an additional 529 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after acquiring an additional 2,296 shares in the last quarter. 15.28% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on PDEX shares. StockNews.com raised Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th. Ascendiant Capital Markets boosted their price target on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, November 11th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.